In those solid tumors with high expression of NQO1, such as lung cancer, and ovarian cancer, NQO1 was regarded as the therapeutic target due to its promotion of cancer cell growth at the early stage of carcinogenesis by binding and stabilizing the mutant or wild-type p53 and then inhibiting its degradation [41]. Here, NQO1 is linked to ovarian carcinoma.